Study guide
4.2 RSI Induction Agents: Pharmacology, Selection & Dosing
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
4.2 RSI Induction Agents: Pharmacology, Selection & Dosing
Key Takeaways Explain This Topic AI
Etomidate (0.3 mg/kg IV) provides rapid, reliable unconsciousness within 15-30 seconds with exceptional hemodynamic stability, making it the preferred induction agent in trauma, undifferentiated shock, and cardiovascular instability.
Etomidate causes transient, reversible adrenal cortical suppression via dose-dependent inhibition of 11-beta-hydroxylase (CYP11B1); randomized trials (KETASED 2009; the 2,365-patient RSI trial, NEJM 2025) found no mortality increase versus ketamine after a single RSI dose.
Ketamine (1–2 mg/kg IV) is an NMDA antagonist that bronchodilates and usually supports blood pressure, but in the RSI trial it caused more peri-intubation cardiovascular collapse than etomidate (22.1% vs 17.0%), so reduce the dose (0.5–1 mg/kg) in catecholamine-depleted shock.
Propofol (1.5-2.5 mg/kg IV) produces rapid GABA-A agonism with potent neuroprotective properties (reducing CMRO2 and ICP), but induces dose-dependent vasodilation and myocardial depression; doses must be reduced to 0.5-1 mg/kg IV or avoided in hemodynamically unstable patients.
Midazolam requires 0.2-0.3 mg/kg IV for true RSI induction; standard emergency doses of 2-5 mg (0.05 mg/kg) provide light conscious sedation rather than general anesthesia, risking catastrophic patient awareness under paralysis and intubation failure.
Last updated: October 2026
4.2 RSI Induction Agents: Pharmacology, Selection & Dosing
Note
Independent BCEMP study resource provided by ExamFinch. Content is organized around official Board of Pharmacy Specialties (BPS) Emergency Medicine Pharmacy examination specifications.
Neuropharmacology of Induction in Rapid Sequence Intubation
Induction in Rapid Sequence Intubation (RSI) requires the rapid intravenous administration of a therapeutic dose of a sedative-hypnotic agent capable of producing immediate loss of consciousness, profound amnesia, and abolition of airway defense reflexes within 15 to 45 seconds. The optimal induction agent must achieve these goals with minimal disruption to systemic hemodynamics, cerebral perfusion pressure, or respiratory mechanics.
Hemodynamic Vulnerability in the Critically Ill
In the emergency department and intensive care unit, up to 10% of patients experience peri-intubation cardiac arrest or profound post-intubation circulatory collapse. Critically ill patients presenting with sepsis, polytrauma, or cardiogenic shock maintain arterial blood pressure and organ perfusion through maximal endogenous sympathetic tone—high circulating levels of epinephrine and norepinephrine coupled with intense systemic vasoconstriction. Administration of an induction agent abruptly eliminates this sympathetic compensatory drive, relaxes vascular tone, and can unmask profound occult hypovolemia. Selecting the appropriate induction agent and tailoring the dose to the patient's underlying physiological reserve is a primary clinical responsibility of the emergency medicine specialist.
- Agent Pharmacology and Clinical Selection
- 1. Etomidate: Hemodynamic Stability & Adrenal Endocrinology
Receptor Target & Mechanism : A carboxylated imidazole derivative that acts as a potent, selective positive allosteric modulator of GABA A \text{GABA}_A GABA A receptors containing β 2 \beta_2 β 2 or β 3 \beta_3 β 3 subunits. Etomidate enhances the inhibitory effects of gamma-aminobutyric acid by increasing chloride channel opening duration, producing rapid central nervous system depression.
Dosing & Pharmacokinetics :
Standard Induction Dose : 0.3 mg/kg IV (based on actual body weight ; 20–30 mg in typical adults).
Shock Dose Adjustment : 0.15 to 0.2 mg/kg IV in profound decompensated shock or severe elderly debility.
Onset & Duration : Onset within 15 to 30 seconds ; duration of action 5 to 10 minutes due to rapid redistribution from the brain into peripheral tissues. Rapidly cleared by hepatic and plasma esterases into inactive metabolites.
Hemodynamic Profile : Etomidate is remarkably hemodynamically neutral. It does not induce myocardial depression, preserves peripheral vascular resistance, maintains heart rate, and preserves coronary artery perfusion pressure. It is the first-line induction agent of choice in undifferentiated shock, polytrauma with hemorrhage, and severe cardiovascular collapse.
Central Nervous System Effects : Decreases the cerebral metabolic rate of oxygen ( CMRO 2 \text{CMRO}_2 CMRO 2 ) by approximately 45%, decreases cerebral blood flow (CBF), and reduces intracranial pressure (ICP) while preserving mean arterial pressure, thereby optimizing cerebral perfusion pressure ( CPP = MAP − ICP \text{CPP} = \text{MAP} - \text{ICP} CPP = MAP − ICP ).
The Adrenal Cortical Suppression Controversy :
Biochemical Mechanism : Etomidate contains an imidazole ring that binds with high affinity to the heme moiety of cytochrome P450 enzymes within the adrenal cortex. It selectively and reversibly inhibits 11-beta-hydroxylase (CYP11B1) , the enzyme responsible for converting 11-deoxycortisol to cortisol and 11-deoxycorticosterone to corticosterone. A single RSI induction dose produces measurable adrenocortical suppression that persists for 12 to 24 hours.
Clinical Trial Evidence : Biochemical adrenal suppression is real, and post-hoc analyses (including a CORTICUS substudy) raised concern in sepsis. Randomized data are reassuring:
KETASED (Lancet 2009, 655 patients): etomidate versus ketamine for emergency intubation showed no difference in maximum SOFA score or 28-day mortality.
RSI trial (Casey et al., NEJM 2025, 2,365 critically ill adults in EDs and ICUs): in-hospital death by day 28 was 28.1% with ketamine vs 29.1% with etomidate (no significant difference), while cardiovascular collapse during intubation was more common with ketamine (22.1% vs 17.0%) , especially in sepsis (30.6% vs 20.9%).
Single-dose etomidate therefore remains a standard induction agent in septic shock and critical illness.
Adverse Effects & Cautions : Transient myoclonus (observed in 30% to 60% of unparalyzed patients, caused by subcortical disinhibition and completely eliminated by concurrent NMBA administration), pain on peripheral injection (secondary to the 35% propylene glycol solvent vehicle), and postoperative nausea and vomiting. Etomidate possesses no analgesic properties .
2. Ketamine: Dissociative Anesthesia, Bronchodilation & Shock Paradox
Receptor Target & Mechanism : A phencyclidine (PCP) derivative that acts as a non-competitive antagonist at the phencyclidine binding site within the N-methyl-D-aspartate (NMDA) receptor-gated calcium ion channel complex. By blocking glutamate transmission, ketamine uncouples the limbic system from the thalamoneocortical cortex, inducing a unique state of dissociative anesthesia (eyes remain open with slow nystagmic gaze, corneal and laryngeal reflexes are preserved, and the patient displays profound amnesia and somatic analgesia).
Dosing & Pharmacokinetics :
Standard Induction Dose : 1 to 2 mg/kg IV (the RSI trial dosed by actual body weight; many references use ideal or lean body weight in obesity; 100–150 mg in typical adults).
Shock Dose Adjustment : 0.5 to 1.0 mg/kg IV in profound, unresuscitated shock.
Onset & Duration : Onset within 30 to 60 seconds ; clinical duration of dissociation is 10 to 20 minutes , with redistribution half-life of 10 to 15 minutes. Metabolized hepatically via CYP3A4/CYP2B6 to norketamine (active metabolite with one-third the potency of ketamine).
Cardiovascular Dual Pharmacology & The Catecholamine-Depleted State :
Normal Physiology : Ketamine stimulates the central sympathetic nervous system and inhibits the neuronal reuptake of catecholamines (norepinephrine and epinephrine). In patients with intact autonomic reserves, this indirect sympathomimetic action elevates systolic and diastolic blood pressure, heart rate, cardiac output, and systemic vascular resistance (SVR).
The Catecholamine-Depleted Paradox : Ketamine is an intrinsic direct negative inotrope and myocardial depressant. Under normal conditions, its indirect central sympathomimetic stimulation completely overshadows this direct cardiac depression. However, in critically ill patients with prolonged, end-stage septic or hemorrhagic shock whose endogenous catecholamine stores are fully exhausted, ketamine's direct myocardial depressant effect is unmasked, which can cause precipitous hypotension or cardiac arrest. Dosing must be reduced to 0.5 to 1.0 mg/kg IV in severely depleted states.
Pulmonary Mechanics : Ketamine is a potent bronchodilator. It relaxes bronchial smooth muscle through catecholamine-mediated β 2 \beta_2 β 2 -adrenergic stimulation and direct vagolytic antagonism of muscarinic receptors. It preserves functional residual capacity and spontaneous respiratory drive. Ketamine is the unquestioned induction agent of choice in acute status asthmaticus and severe reactive bronchospasm.
Intracranial Pressure (Debunking the Dogma) : Historical dogma claimed ketamine increased ICP and was strictly contraindicated in traumatic brain injury (TBI). Modern neurocritical care trials (Zeiler et al., 2014; Ballow et al., 2014) demonstrate that when mechanical ventilation is controlled and normocapnia is maintained (avoiding hypoventilation-induced hypercapnic cerebral vasodilation), ketamine does not increase ICP. By supporting systemic blood pressure, ketamine maintains cerebral perfusion pressure, making it safe and effective in neurotrauma.
Emergence Phenomena : Vivid dreams, hallucinations, and psychotomimetic agitation occur in 10% to 20% of adult patients upon awakening. These are effectively mitigated by post-intubation co-administration of low-dose benzodiazepines or propofol.
3. Propofol: Neuroprotection, Rapid Clearance & Vasodilatory Hypotension
Receptor Target & Mechanism : An alkylphenol derivative (2,6-diisopropylphenol) formulated in a 10% oil-in-water lipid emulsion (soybean oil, glycerol, and egg lecithin). It binds to β \beta β -subunits of the GABA A \text{GABA}_A GABA A receptor, directly activating and allosterically enhancing inhibitory chloride channel conductance. It also inhibits NMDA receptors and modulates cannabinoid receptor systems.
Dosing & Pharmacokinetics :
Standard Induction Dose : 1.5 to 2.5 mg/kg IV (based on ideal body weight ; 100–150 mg in typical adults).
Shock / Hemodynamically Fragile Dose : 0.5 to 1.0 mg/kg IV (or avoided entirely in shock states).
Onset & Duration : Ultra-rapid onset of 15 to 30 seconds ; ultra-short clinical duration of 5 to 8 minutes secondary to rapid redistribution. Rapidly metabolized hepatically by glucuronidation and sulfation.
Cardiovascular Toxicity : Propofol is the most hemodynamically destabilizing induction agent. It induces marked arterial and venous vasodilation by reducing sympathetic vasoconstrictor tone and directly relaxing vascular smooth muscle. Furthermore, it exerts direct dose-dependent negative inotropic effects on the myocardium and impairs baroreceptor reflex responses. Mean arterial pressure typically falls by 20% to 40% following bolus administration. It is contraindicated as an induction monotherapy in hypovolemia, trauma, or septic shock.
Neuroprotective Properties : Propofol markedly reduces CMRO 2 \text{CMRO}_2 CMRO 2 (by up to 36%), decreases CBF, and causes profound reductions in ICP. It possesses potent anticonvulsant properties, terminating status epilepticus by suppressing epileptogenic electrical foci. It is the agent of choice for RSI in refractory status epilepticus and severe traumatic brain injury with preserved systemic hemodynamics.
Allergy Nuances : Egg allergy is not an absolute contraindication unless the patient has a documented history of severe anaphylaxis to egg yolk lecithin (most egg allergies involve egg white ovalbumin). Formulated at 1.1 kcal/mL in lipid emulsion, which must be tracked during continuous ICU infusions.
4. Midazolam: The 'Sedative vs. Induction' Dosing Fallacy
Receptor Target & Mechanism : A water-soluble imidazobenzodiazepine that crosses the blood-brain barrier rapidly and acts as a positive allosteric modulator of GABA A \text{GABA}_A GABA A receptors, increasing chloride ion influx frequency.
Dosing & Pharmacokinetics :
True RSI Induction Dose : 0.2 to 0.3 mg/kg IV (15 to 25 mg in a typical 70-kg adult).
Onset & Duration : Unacceptably slow onset of 90 to 180 seconds (even longer in elderly or low-cardiac-output patients); prolonged clinical duration of 15 to 30 minutes (up to hours in renal/hepatic failure due to accumulation of active 1-hydroxymidazolam glucuronide).
The Critical Clinical Pitfall (Sedation vs. Induction) : Emergency clinicians frequently order 2 to 5 mg IV of midazolam (0.03 to 0.05 mg/kg) under the mistaken belief that it serves as an RSI induction agent. A 2 to 5 mg dose provides light conscious sedation and anxiolysis; it does not induce general anesthesia, loss of consciousness, or suppression of airway reflexes. Paralyzing a patient who has received only 2 to 5 mg of midazolam results in catastrophic awareness during paralysis , inflicting extreme psychological terror and triggering massive autonomic hypertension and tachycardia. Furthermore, when midazolam is pushed at true induction doses (0.2–0.3 mg/kg), its onset is unacceptably delayed (2–3 minutes) and it produces severe peripheral vasodilation and myocardial depression comparable to propofol. Midazolam is considered a distinctly inferior primary induction agent for emergency RSI.
RSI Induction Agent Comparison Matrix
Parameter Etomidate Ketamine Propofol Midazolam
Primary Receptor GABA A \text{GABA}_A GABA A ( β 2 / β 3 \beta_2/\beta_3 β 2 / β 3 subunits) NMDA receptor antagonist GABA A \text{GABA}_A GABA A agonist GABA A \text{GABA}_A GABA A allosteric modulator
- Standard RSI Dose 0.3 mg/kg IV 1–2 mg/kg IV 1.5–2.5 mg/kg IV 0.2–0.3 mg/kg IV
- Shock RSI Dose 0.15–0.2 mg/kg IV 0.5–1.0 mg/kg IV 0.5–1.0 mg/kg IV Avoid in shock
- Weight Metric Actual Body Weight Ideal or actual (RSI trial used actual) Ideal Body Weight Actual Body Weight
- Onset Time 15–30 seconds 30–60 seconds 15–30 seconds 90–180 seconds
- Clinical Duration 5–10 minutes 10–20 minutes 5–8 minutes 15–30 minutes
Blood Pressure / SVR Neutral (no change) ↑ \uparrow ↑ BP, ↑ \uparrow ↑ SVR, ↑ \uparrow ↑ CO ↓ ↓ \downarrow\downarrow ↓↓ BP (20–40% drop), ↓ \downarrow ↓ SVR ↓ \downarrow ↓ BP, ↓ \downarrow ↓ SVR
Heart Rate Neutral ↑ \uparrow ↑ Heart rate Neutral or ↓ \downarrow ↓ Heart rate Neutral or ↑ \uparrow ↑ Heart rate
ICP / CMRO2 ↓ ↓ \downarrow\downarrow ↓↓ ICP, ↓ ↓ \downarrow\downarrow ↓↓ CMRO 2 \text{CMRO}_2 CMRO 2 , preserves CPP Neutral ICP (with normocapnia), preserves CPP ↓ ↓ \downarrow\downarrow ↓↓ ICP, ↓ ↓ \downarrow\downarrow ↓↓ CMRO 2 \text{CMRO}_2 CMRO 2 , risk ↓ \downarrow ↓ CPP ↓ \downarrow ↓ ICP, ↓ \downarrow ↓ CMRO 2 \text{CMRO}_2 CMRO 2
Airway / Bronchial Neutral Potent bronchodilation Moderate bronchodilation Neutral
First-Line Indications Trauma, undifferentiated shock, cardiac arrest, aortic dissection Status asthmaticus, severe sepsis, shock (with volume), analgesia Status epilepticus, neurotrauma (stable BP), hyperactive airway Refractory seizures (not preferred for primary RSI)
Primary Cautions 11- β \beta β -hydroxylase adrenal suppression, myoclonus Catecholamine-depleted shock (negative inotrope), emergence Severe hypotension, myocardial depression, egg/soy vehicle Underdosing awareness risk (2–5 mg fallacy), delayed onset
- Worked Clinical Case & Practice Pearls
- Clinical Vignette
A 42-year-old female (actual weight 65 kg, height 5'5") with a history of severe brittle asthma is brought by EMS to the emergency department in near-fatal status asthmaticus. She is sitting in a tripod position, using accessory muscles of respiration, and unable to speak more than single syllables. Vital signs: blood pressure 152/92 mmHg, heart rate 134 bpm, respiratory rate 38 breaths/min, and S p O 2 SpO_2 Sp O 2 88% on a non-rebreather mask. Bilateral breath sounds reveal marked expiratory wheezing with areas of 'silent chest' at the lung bases. Arterial blood gas demonstrates acute respiratory muscle fatigue and carbon dioxide narcosis: pH 7.14, PaCO 2 \text{PaCO}_2 PaCO 2 74 mmHg, PaO 2 \text{PaO}_2 PaO 2 58 mmHg, and HCO 3 − \text{HCO}_3^- HCO 3 − 24 mEq/L. Despite continuous nebulized albuterol, ipratropium, IV magnesium sulfate (2 g), and IV methylprednisolone (125 mg), she becomes increasingly somnolent. The emergency team initiates RSI.
Pharmacotherapeutic Care Plan
Preoxygenation : Apply 100% F i O 2 FiO_2 F i O 2 via NIPPV with low PEEP (5 cmH 2 O \text{cmH}_2\text{O} cmH 2 O ) and high pressure support to overcome intrinsic PEEP and maximize denitrogenation.
Induction Agent Selection : Ketamine 2.0 mg/kg IV × \times × 65 kg = 130 mg IV push .
Pharmacological Rationale : Ketamine directly relaxes bronchial smooth muscle through β 2 \beta_2 β 2 -adrenoceptor stimulation via endogenous catecholamine release and direct vagolytic muscarinic antagonism. It maintains hemodynamic stability and provides immediate dissociative unconsciousness without worsening respiratory acidosis.
Neuromuscular Blocker Selection : Rocuronium 1.2 mg/kg IV × \times × 65 kg = 78 mg IV (rounded to 80 mg) .
Rationale : Provides complete motor paralysis within 60 seconds without triggering histamine release (which can exacerbate bronchospasm).
Outcome : The patient is successfully intubated on the first attempt with a 7.5-mm ETT. Mechanical ventilation is initiated with an obstructive lung strategy (low tidal volume 6 mL/kg, low respiratory rate 10–12 breaths/min, and long expiratory time to prevent dynamic hyperinflation and auto-PEEP). Post-intubation ketamine continuous infusion (1 mg/kg/h) and propofol infusion (20 mcg/kg/min) are started immediately.
Warning
Never administer a 'standard' 2 to 5 mg IV dose of midazolam as the sole induction agent for RSI. Administering an NMBA after 2 to 5 mg of midazolam induces flaccid paralysis in an awake patient who retains sensory perception, pain, and cognitive processing. If midazolam is chosen for true induction, the evidence-based dose is 0.2 to 0.3 mg/kg IV, accompanied by vasopressor readiness.